METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to train immune system against aggressive breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a vaccine called STEMVAC, given with chemotherapy, for people with a hard-to-treat breast cancer that has spread. The vaccine is designed to teach the immune system to attack cancer stem cells. About 20 adults with PD-L1 negative, metastatic triple-negative breas…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: ⭐️ VACCINE ⭐️
Last updated May 16, 2026 22:27 UTC
-
Custom-Made vaccine takes on tough breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor, given alone or with drugs that boost the immune system (pembrolizumab or ipilimumab). The goal is to see if the vaccine is safe and can help the immune system fight triple negative breast cancer …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:37 UTC
-
Personalized vaccine joins immunotherapy in fight against metastatic breast cancer
Disease control Recruiting nowThis study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive either the…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New combo therapy targets hard-to-treat breast cancer
Disease control Recruiting nowThis study tests whether adding high-dose radiation to standard immunotherapy (pembrolizumab) and chemotherapy can help people with a specific type of advanced breast cancer (PD-L1 positive, triple-negative) that has spread. About 29 adults will receive the combination treatment.…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 16, 2026 22:28 UTC
-
New drug combo targets Hard-to-Treat breast cancer in small trial
Disease control Recruiting nowThis study tests whether adding tamoxifen (a hormone therapy) to a type of chemotherapy (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. The trial includes 30 adults whose cancer has a…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo targets Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs, neratinib and ruxolitinib, is safe and effective for people with metastatic triple-negative breast cancer that has come back on the chest wall after chemotherapy. About 20 women aged 18 and older will receive the drug comb…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New vaccine-immunotherapy combo targets breast cancer brain metastases
Disease control Recruiting nowThis study tests a combination of a dendritic cell vaccine (which trains the immune system to attack cancer) and pembrolizumab (an immunotherapy drug) in people with breast cancer that has spread to the brain. The goal is to see if this treatment can shrink brain tumors. The stud…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a parasite drug boost cancer immunotherapy? new trial investigates
Disease control Recruiting nowThis study tests whether adding ivermectin (a common anti-parasite drug) to standard immunotherapy can help shrink tumors in people with metastatic triple-negative breast cancer. About 34 adults whose cancer has spread will receive the combination. The goal is to find the best do…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New triple-drug combo targets hard-to-treat breast cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding an experimental drug (ZEN003694) to standard immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) is safe and tolerable for people with advanced triple-negative breast cancer that has spread. About 57 participants will r…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug duo targets hard-to-treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of two drugs given together for people with advanced breast cancer or other solid tumors that have a protein called HER2. The drugs are pidnarulex (which stops cancer cells from repairing themselves) and trastuzumab deruxtecan…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for tough breast cancer: early trial combines three drugs
Disease control Recruiting nowThis early-phase study tests a new drug, ASTX727, added to standard chemotherapy and immunotherapy for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink or stabilize tu…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
App-Based monitoring aims to boost quality of life in advanced breast cancer
Symptom relief Recruiting nowThis study tests whether a digital platform called CUREETY TECHCARE can improve quality of life and reduce hospital visits for people with metastatic triple-negative breast cancer starting their first treatment. About 472 participants will either use the app to report symptoms an…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Symptom relief
Last updated May 16, 2026 22:32 UTC
-
New study tracks Real-World impact of targeted cancer drugs in advanced breast cancer
Knowledge-focused Recruiting nowThis study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these treatments control the cancer in real-world settings. The goal is to gather information…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC